ADHD Lisdexamfetamine IND Melatonine Molindone ALS Arimoclomol Masitinib Sodium phenylbutyrate / tauroursodeoxycholic acid Dementia Donanemab Gantenerumab Depression Agomelatine IND Bupropion / dextromethorphan Esketamine IND Duchenne Fordadistrogene movaparvovec Givinostat Golodirsen Vamorolone Viltolarsen Epilepsy Cannabidiol IND Fenfluramine IND Ganaxolone Lacosamide IND Eye disorders Aflibercept Diabetic macular edema BS Eylea is indicated in preterm infants for the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease. IND Avacincaptad pegol Faricimab Treatment of neovascular (wet) age-related macular degeneration (nAMD). Treatment of visual impairment due to diabetic macular oedema (DME). Lenadogene nolparvovec Pegcetacoplan Perfluorohexyloctane Phentolamine Polihexanide Ranibizumab Wet age-related macular degeneration (AMD). BS Treatment of neovascular age-related macular degeneration (AMD) Wet age-related macular degeneration (AMD) BS Reproxalap Sepofarsen Headache Atogepant Dihydroergotamine Eptinezumab Lasmiditan Meloxicam / rizatriptan Rimegepant Acute treatment of migraine with or without aura in adults Preventive treatment of episodic migraine in adults who have at least 4 migraine attacks per month Multiple sclerosis Dimethyl fumarate IND Natalizumab BS Teriflunomide Volwassenen met 'relapsing remitting' multipele sclerose (RRMS). G Volwassenen met 'relapsing remitting' multipele sclerose (RRMS). G Ublituximab Muscular diseases other Bidridistrogene xeboparvovec Dantroleen G Daxibotulinumtoxine A Deoxythymidine / deoxycytidine Di-deuterated ethyl linoleate Efgartigimod Omaveloxolone Ravulizumab IND Rozanolixizumab Satralizumab IND Zilucoplan Neurological disorders other Cannabidiol Clazosentan Eladocagene exuparvovec Inebilizumab Ravulizumab IND Satralizumab Tiratricol Tominersen Trofinetide Vutrisiran Other psychiatry Dexmedetomidine Pain Bupivacaine Buprenorfine IND Fasinumab SDN037 Parkinson's Levodopa / carbidopa SMA Risdiplam 5q SMA in patients 2 months of age and older, with a clinical diagnosis of Type 1, Type 2 or Type 3 SMA or with one to four SMN2 copies. Extension of indication to include treatment of patients below 2 months of age. IND Schizophrenia, psychosis, bipolar disorder Roluperidon Sleep disorders Daridorexant JZP-258 Natriumoxybaat controlled release Pitolisant Ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by, or who have not tolerated, OSA primary therapy, such as continuous positive airway pressure (CPAP). Extension of indication to include treatment of narcolepsy with or without cataplexy in adolescents and children from the age of 6 years. IND